Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Nature Immunology|April 27, 2023
Human memory B cells show plasticity and adopt multiple fates upon recall response to SARS-CoV-2Yves Zurbuchen, Jan Michler, Patrick Taeschler, et al.
Nature Medicine|January 18, 2022
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variantYu Gao, Curtis Cai, Alba Grifoni, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2023
Functional SARS-CoV-2 cross-reactive CD4<sup>+</sup> T cells established in early childhood decline with ageMarion Humbert, Anna Olofsson, David Wullimann, et al.
Molecular Therapy. Advances|May 15, 2026
A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinationsSoo Aleman, Gustaf Ahlén, Jingyi Yan, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 12, 2024
Direct Current Stimulation of Prefrontal Cortex Is Not Effective in Progressive Supranuclear Palsy: A Randomized TrialArianna Cappiello, Filomena Abate, Sarah Adamo, et al.
Ebiomedicine|July 15, 2023
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Molecular Medicine (Cambridge, Mass.)|May 13, 2022
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccineCaroline Boulouis, Tobias Kammann, Angelica Cuapio, et al.
Cell Reports|December 21, 2017
HIV-Specific CD8<sup>+</sup> T Cells Exhibit Reduced and Differentially Regulated Cytolytic Activity in Lymphoid TissueMorgan A Reuter, Perla M Del Rio Estrada, Marcus Buggert, et al.
Allergy|May 14, 2022
T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19Patrick Taeschler, Sarah Adamo, Yun Deng, et al.
Ebiomedicine|May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunityPuran Chen, Peter Bergman, Ola Blennow, et al.
Pageof 14